Zera Health vs Nova
Fifty states against two, at a forty-dollar difference on the opening injection.
Zera Health
Editorial
$129/mo
Three lines with the dosing form stated on each. The $129 semaglutide injection is described by Zera as a low-dose weekly line, the $169 oral is a daily dissolving tablet, and tirzepatide is $199 weekly. That qualifier travels with the figure: a low-dose rate is not priced against a standard starting dose. Zera states each rate holds at every dose. Coverage is stated across 50 states.
Pick it for: Buyers anywhere outside Texas and Florida
Nova
Editorial
$139/mo
Two injection lines quoted as all-in figures that already contain a required care fee: $198 for semaglutide and $210 for tirzepatide, with shipping stated as included. A required fee named inside the price is a different proposition from one a buyer meets at checkout. The oral lines are quoted lower, at $156 and $174, but the oral semaglutide bills its first three months together at $269. Coverage is two states.
Pick it for: Buyers in those two states who want a mandatory fee priced in
Our verdict
Zera Health ships to fifty states and states its rates hold; Nova reaches Texas and Florida and its rates climb. For most readers this is settled by the map.
What actually separates them
Zera Health and Nova state different things about published price and where you can use it. Everything else they publish, they publish the same way.
Nova costs $10 more than Zera Health — 8% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,548 at Zera Health against $1,668 at Nova — a difference of $120.
| Zera Health | Nova | |
|---|---|---|
| Published price | $129/mo | $139/mo |
| Where you can use it | 50 states | 2 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.